SCHEMBL92824

SCHEMBL92824

CCC(=O)NS(=O)(=O)C1CCN(C)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.34
HTR2C P28335 2/20 0.34
HTR1A P08908 1/20 0.34
HTR1D P28221 1/20 0.34
HTR1B P28222 1/20 0.34
HTR1E P28566 1/20 0.34
HTR1F P30939 1/20 0.34
HTR6 P50406 1/20 0.34
HTR4 Q13639 1/20 0.34
KDM1A O60341 1/20 0.34
NAMPT P43490 1/20 0.33
MMP1 P03956 1/20 0.33
MMP7 P09237 1/20 0.33
MMP12 P39900 1/20 0.33
ECE1 P42892 1/20 0.33
MMP13 P45452 1/20 0.33
GNAI3 P08754 2/20 0.33
GNAO1 P09471 2/20 0.33
GNAI1 P63096 2/20 0.33
ALDH1A1 P00352 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1161221 0.85 MMP1 (0.37) KDM1AMMP1MMP7MMP12ECE1
SCHEMBL10092606 0.77 SCN9A (0.33) MMP1MMP7MMP12ECE1MMP13
SCHEMBL84992 0.76 SCN9A (0.35) HTR1FNAMPTALDH1A1
SCHEMBL92833 0.71 CYP2C9 (0.37) HTR1AALDH1A1THRBSIGMAR1
SCHEMBL29764410 0.71 CA1 (0.40) HTR2AHTR2CKDM1AGNAI3GNAO1
SCHEMBL2743288 0.71 NCF1 (0.33) HTR2AHTR2CHTR1AHTR1DHTR1B
SCHEMBL10265277 0.71 SIGMAR1 (0.49) ALDH1A1SIGMAR1
SCHEMBL12820021 0.71 HDAC3 (0.46) KDM1AMMP1MMP7MMP12ECE1
SCHEMBL13162843 0.69 NCF1 (0.39) HTR2AHTR2CNAMPTGNAI3GNAO1
SCHEMBL1646318 0.68 CA12 (0.41) HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129410-B2 Sleep maintenance insomnia; circadian rhythm abnormalities; side effect reduction HYPNION, INC. (US) 2012-03-06 US disclosed
US-8101596-B2 Loxapine analogs and methods of use thereof HYPNION INC. (US) 2012-01-24 US disclosed
US-20090186872-A1 LOXAPINE ANALOGS AND METHODS OF USE THEREOF EDGAR DALE M 2009-07-23 US disclosed
US-7563785-B2 Quetiapine analogs and methods of use thereof HYPNION, INC. (US) 2009-07-21 US disclosed
US-20080214539-A1 Benzisoxazole Piperidine Compounds and Methods of Use Thereof HYPNION, INC. 2008-09-04 US disclosed
US-20070004752-A1 Benzisoxazole piperazine compounds and methods of use thereof HYPNION, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214539-A1 Benzisoxazole Piperidine Compounds and Methods of Use Thereof GABRA5, GABRE, HCRTR2 HTR2A 284/4885HTR2C 89/4885HTR1A 278/4885
US-20070004752-A1 Benzisoxazole piperazine compounds and methods of use thereof GABRA5, HCRTR2, HCRTR1 HTR2A 128/4885HTR2C 48/4885HTR1A 248/4885
US-20090186872-A1 LOXAPINE ANALOGS AND METHODS OF USE THEREOF HCRTR2, HCRTR1, HTR3B HTR2A 9/4885HTR2C 4/4885HTR1A 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.